Table 1

|  |  |
| --- | --- |
| Variable | **N = 528** |
| **Age at enrolment, median (IQR) (years)** | 36.0 (31.0, 43.0) |
| **Gender, n (%)** |  |
| Female | 269 (50.9%) |
| Male | 256 (48.5%) |
| Unknown | 3 (0.6%) |
| **Ethnicity, n (%)** |  |
| Black African | 421 (79.7%) |
| Other | 105 (19.9%) |
| Unknown | 2 (0.4%) |
| **Duration of current illness, median (IQR) (days)** | 14.0 (12.0, 21.0) |
| **log10 viral load** | 10.7 (7.4, 12.3) |
| **Total CD4 count** | 33.0 (15.0, 61.0) |
| **White cell count X109** | 5.4 (3.6, 8.1) |
| **Lymphocyte count X109** | 0.8 (0.4, 1.8) |
| **Neutrophils** | 3.2 (1.5, 8.3) |
| **Weight loss** | 435 (82.4%) |
| **Tuberculosis** | 445 (84.3%) |
| **Cryptococcus neoformans** | 30 (5.7%) |
| **Pneumonia** | 62 (11.7%) |
| **Staph aureus** | 1 (0.2%) |
| **Kaposis sarcoma** | 6 (1.1%) |
| **Cytomegalovirus** | 1 (0.2%) |
| **HSV** | 8 (1.5%) |
| **HepB** | 18 (3.4%) |
| **Candida** | 29 (5.5%) |
| **GE/c diff** | 18 (3.4%) |
| **Parvo B19** | 1 (0.2%) |
| **Syphilis** | 17 (3.2%) |
| **B menigitis** | 5 (0.9%) |
| **UTI / Leptospirosis** | 7 (1.3%) |
| **PCP** | 4 (0.8%) |
| **COVID-19** | 2 (0.4%) |
| **Neurocysticercosis** | 2 (0.4%) |

Table 2:

|  |  |  |  |
| --- | --- | --- | --- |
| Variable | **Female**, N = 269 | **Male**, N = 256 | **p-value** |
| **Age at enrolment, median (IQR) (years)** | 35.0 (31.0, 42.0) | 37.0 (32.0, 44.5) | 0.017 |
| **Ethnicity, n (%)** |  |  | 0.6 |
| Black African | 210 (78.1%) | 210 (82.0%) |  |
| Other | 58 (21.6%) | 45 (17.6%) |  |
| Unknown | 1 (0.4%) | 1 (0.4%) |  |
| **Duration of current illness, median (IQR) (days)** | 14.0 (11.5, 21.0) | 14.0 (12.8, 21.0) | 0.6 |
| **log10 viral load** | 10.4 (7.2, 12.2) | 10.7 (7.7, 12.5) | 0.8 |
| **Total CD4 count** | 33.0 (15.0, 58.0) | 32.5 (12.8, 64.0) | >0.9 |
| **Sodium** | 134.0 (131.0, 138.0) | 133.0 (129.0, 136.0) | <0.001 |
| **Potassium** | 3.9 (3.5, 4.4) | 4.2 (3.9, 4.7) | <0.001 |
| **Haemoglobin** | 8.3 (7.1, 9.6) | 9.3 (7.9, 10.9) | <0.001 |
| **White cell count** | 5.3 (3.5, 8.0) | 5.4 (3.8, 8.3) | 0.8 |
| **Lymphocyte count** | 0.9 (0.3, 2.4) | 0.8 (0.5, 1.4) | 0.8 |
| **Neutrophils** | 3.3 (1.5, 10.2) | 3.2 (1.3, 7.3) | 0.6 |
| **Weight loss** | 225 (83.6%) | 208 (81.3%) | 0.5 |
| **Tuberculosis** | 221 (82.2%) | 222 (86.7%) | 0.2 |
| **Cryptococcus neoformans** | 12 (4.5%) | 18 (7.0%) | 0.2 |
| **Pneumonia** | 30 (11.2%) | 32 (12.5%) | 0.6 |
| **Staph aureus** | 0 (0.0%) | 1 (0.4%) | 0.5 |
| **Kaposis sarcoma** | 4 (1.5%) | 2 (0.8%) | 0.7 |
| **Cytomegalovirus** | 0 (0.0%) | 1 (0.4%) | 0.5 |
| **HSV** | 4 (1.5%) | 4 (1.6%) | >0.9 |
| **HepB** | 7 (2.6%) | 11 (4.3%) | 0.3 |
| **Candida** | 17 (6.3%) | 12 (4.7%) | 0.4 |
| **GE/c diff** | 11 (4.1%) | 7 (2.7%) | 0.4 |
| **Parvo B19** | 1 (0.4%) | 0 (0.0%) | >0.9 |
| **Syphilis** | 8 (3.0%) | 9 (3.5%) | 0.7 |
| **B menigitis** | 4 (1.5%) | 1 (0.4%) | 0.4 |
| **UTI / Leptospirosis** | 1 (0.4%) | 6 (2.3%) | 0.063 |
| **PCP** | 2 (0.7%) | 2 (0.8%) | >0.9 |
| **COVID-19** | 1 (0.4%) | 1 (0.4%) | >0.9 |
| **Neurocysticercosis** | 0 (0.0%) | 2 (0.8%) | 0.2 |

Table 3

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable | **0 - 30**, N = 246 | **31 - 60**, N = 144 | **61 - 100**, N = 132 | **p-value** |
| **Age at enrolment, median (IQR) (years)** | 35.0 (30.0, 42.0) | 37.0 (32.0, 43.3) | 37.0 (32.0, 46.0) | 0.013 |
| **Gender** |  |  |  | 0.10 |
| Female | 124 (50.4%) | 82 (56.9%) | 61 (46.2%) |  |
| Male | 122 (49.6%) | 60 (41.7%) | 70 (53.0%) |  |
| Unknown | 0 (0.0%) | 2 (1.4%) | 1 (0.8%) |  |
| **Ethnicity, n(%)** |  |  |  | 0.5 |
| Black African | 203 (82.5%) | 113 (78.5%) | 101 (76.5%) |  |
| Other | 42 (17.1%) | 31 (21.5%) | 30 (22.7%) |  |
| Unknown | 1 (0.4%) | 0 (0.0%) | 1 (0.8%) |  |
| **Duration of current illness, median (IQR) (days)** | 14.0 (14.0, 21.0) | 14.0 (9.8, 21.8) | 14.0 (7.0, 21.0) | 0.059 |
| **log10 viral load** | 11.6 (9.3, 12.7) | 8.3 (6.2, 12.1) | 8.5 (3.9, 11.4) | 0.001 |
| **Total CD4 count** | 13.0 (6.0, 22.0) | 46.0 (37.8, 53.0) | 80.0 (70.0, 89.0) | <0.001 |
| **Sodium** | 134.0 (130.0, 137.0) | 134.0 (129.5, 137.0) | 133.0 (130.0, 136.0) | 0.9 |
| **Potassium** | 4.0 (3.6, 4.5) | 4.1 (3.7, 4.5) | 4.3 (3.6, 4.8) | 0.053 |
| **Haemoglobin** | 8.5 (7.4, 9.9) | 8.7 (7.2, 10.0) | 9.2 (7.5, 11.0) | 0.020 |
| **White cell count X109** | 5.0 (2.9, 7.3) | 5.7 (4.1, 8.9) | 6.5 (4.4, 9.3) | <0.001 |
| **Lymphocyte count X109** | 0.6 (0.3, 1.3) | 1.0 (0.5, 2.0) | 1.2 (0.7, 2.8) | 0.027 |
| **Neutrophils** | 2.3 (1.0, 5.7) | 5.3 (1.6, 14.8) | 5.4 (3.3, 10.9) | 0.004 |
| **Weight loss** | 211 (85.8%) | 121 (84.0%) | 103 (78.0%) | 0.2 |
| **Tuberculosis** | 211 (85.8%) | 123 (85.4%) | 109 (82.6%) | 0.7 |
| **Cryptococcus neoformans** | 16 (6.5%) | 4 (2.8%) | 10 (7.6%) | 0.2 |
| **Pneumonia** | 28 (11.4%) | 18 (12.5%) | 16 (12.1%) | >0.9 |
| **Staph aureus** | 1 (0.4%) | 0 (0.0%) | 0 (0.0%) | >0.9 |
| **Kaposis sarcoma** | 6 (2.4%) | 0 (0.0%) | 0 (0.0%) | 0.039 |
| **Cytomegalovirus** | 0 (0.0%) | 1 (0.7%) | 0 (0.0%) | 0.5 |
| **HSV** | 3 (1.2%) | 3 (2.1%) | 2 (1.5%) | 0.9 |
| **HepB** | 9 (3.7%) | 7 (4.9%) | 2 (1.5%) | 0.3 |
| **Candida** | 16 (6.5%) | 12 (8.3%) | 1 (0.8%) | 0.016 |
| **GE/c diff** | 10 (4.1%) | 6 (4.2%) | 2 (1.5%) | 0.4 |
| **Parvo B19** | 0 (0.0%) | 1 (0.7%) | 0 (0.0%) | 0.5 |
| **Syphilis** | 7 (2.8%) | 8 (5.6%) | 1 (0.8%) | 0.064 |
| **B menigitis** | 3 (1.2%) | 1 (0.7%) | 1 (0.8%) | >0.9 |
| **UTI / Leptospirosis** | 4 (1.6%) | 0 (0.0%) | 3 (2.3%) | 0.2 |
| **PCP** | 3 (1.2%) | 1 (0.7%) | 0 (0.0%) | 0.8 |
| **COVID-19** | 1 (0.4%) | 1 (0.7%) | 0 (0.0%) | >0.9 |
| **Neurocysticercosis** | 1 (0.4%) | 1 (0.7%) | 0 (0.0%) | >0.9 |

Table 4

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Variable | **no-AI**, N = 502 | **AI**, N = 26 |  | **p-value** | **PAI**, N = 20 | **SAI**, N = 6 | **p-value** |
| **Age at enrolment, median (IQR) (years)** | 36.0 (31.0, 43.0) | 36.0 (31.5, 46.0) |  | 0.5 | 36.0 (31.0, 42.3) | 43.0 (35.3, 51.5) | 0.3 |
| **Gender, n (%)** |  |  |  | 0.9 |  |  | 0.7 |
| Female | 255 (50.8%) | 14 (53.8%) |  |  | 10 (50.0%) | 4 (66.7%) |  |
| Male | 244 (48.6%) | 12 (46.2%) |  |  | 10 (50.0%) | 2 (33.3%) |  |
| Unknown | 3 (0.6%) | 0 (0.0%) |  |  |  |  |  |
| **Ethnicity, n (%)** |  |  |  | 0.4 |  |  | >0.9 |
| Black African | 398 (79.3%) | 23 (88.5%) |  |  | 18 (90.0%) | 5 (83.3%) |  |
| Other | 102 (20.3%) | 3 (11.5%) |  |  | 2 (10.0%) | 1 (16.7%) |  |
| Unknown | 2 (0.4%) | 0 (0.0%) |  |  |  |  |  |
| **Duration of current illness, median (IQR) (days)** | 14.0 (12.0, 21.0) | 14.0 (14.0, 30.0) |  | 0.6 | 14.0 (10.8, 15.8) | 30.0 (30.0, 30.0) | 0.013 |
| **Random cortisol** | 477.0 (372.5, 577.0) | 313.0 (251.5, 379.5) |  | <0.001 | 334.5 (254.5, 376.5) | 272.5 (237.5, 365.3) | 0.7 |
| **Basal cortisol** | 466.0 (355.8, 572.3) | 300.0 (196.3, 363.5) |  | <0.001 | 300.0 (190.3, 338.0) | 289.0 (213.8, 433.3) | 0.7 |
| **Stimulated cortisol** | 722.0 (633.0, 853.5) | 391.0 (320.8, 441.0) |  | <0.001 | 410.5 (339.3, 439.0) | 357.0 (197.8, 448.8) | 0.6 |
| **ACTH** | 32.0 (20.1, 48.2) | 28.0 (22.1, 69.6) |  | 0.6 | 42.4 (25.2, 76.0) | 9.5 (7.3, 12.7) | <0.001 |
| **BP (systolic)** | 111.0 (102.0, 125.0) | 120.0 (106.5, 128.8) |  | 0.2 | 120.0 (109.5, 128.5) | 115.0 (102.0, 125.8) | 0.6 |
| **BP (diastolic)** | 70.0 (60.0, 79.0) | 72.0 (64.8, 80.0) |  | 0.083 | 71.0 (68.3, 80.0) | 73.0 (61.0, 78.3) | 0.8 |
| **Heart rate** | 90.5 (78.8, 109.0) | 86.5 (77.8, 108.0) |  | 0.7 | 91.0 (76.8, 110.3) | 85.0 (82.5, 86.8) | 0.8 |
| **Hypotension** | 40 (8.0%) | 1 (3.8%) |  | 0.7 | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Weakness** | 403 (80.3%) | 21 (80.8%) |  | >0.9 | 15 (75.0%) | 6 (100.0%) | 0.3 |
| **Tiredness** | 404 (80.5%) | 23 (88.5%) |  | 0.4 | 17 (85.0%) | 6 (100.0%) | >0.9 |
| **Poor appetite** | 357 (71.1%) | 22 (84.6%) |  | 0.14 | 18 (90.0%) | 4 (66.7%) | 0.2 |
| **Weight loss** | 414 (82.5%) | 21 (80.8%) |  | 0.8 | 18 (90.0%) | 3 (50.0%) | 0.062 |
| **Increased pigmentation of the skin** | 232 (46.2%) | 9 (34.6%) |  | 0.2 | 7 (35.0%) | 2 (33.3%) | >0.9 |
| **Nausea** | 249 (49.6%) | 16 (61.5%) |  | 0.2 | 11 (55.0%) | 5 (83.3%) | 0.4 |
| **Vomiting** | 133 (26.5%) | 8 (30.8%) |  | 0.6 | 6 (30.0%) | 2 (33.3%) | >0.9 |
| **Liking for salt** | 256 (51.0%) | 18 (69.2%) |  | 0.070 | 13 (65.0%) | 5 (83.3%) | 0.6 |
| **Hypoglycaemia** | 11 (2.2%) | 0 (0.0%) |  | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Loss of consciousness** | 7 (1.4%) | 0 (0.0%) |  | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Diarrhoea** | 205 (40.8%) | 8 (30.8%) |  | 0.3 | 5 (25.0%) | 3 (50.0%) | 0.3 |
| **Dizziness** | 222 (44.2%) | 13 (50.0%) |  | 0.6 | 10 (50.0%) | 3 (50.0%) | >0.9 |
| **Shock** | 5 (1.0%) | 0 (0.0%) |  | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Anorexia** | 220 (43.8%) | 8 (30.8%) |  | 0.2 | 7 (35.0%) | 1 (16.7%) | 0.6 |
| **Loss of axillary and pubic hair, if female** |  |  |  | 0.8 |  |  | 0.7 |
| No | 191 (38.0%) | 11 (42.3%) |  |  | 8 (40.0%) | 3 (50.0%) |  |
| Not applicable | 222 (44.2%) | 12 (46.2%) |  |  | 10 (50.0%) | 2 (33.3%) |  |
| Yes | 89 (17.7%) | 3 (11.5%) |  |  | 2 (10.0%) | 1 (16.7%) |  |
| **Any postural drop in blood pressure** | 16 (3.2%) | 2 (7.7%) |  | 0.2 | 1 (5.0%) | 1 (16.7%) | 0.4 |
| **Presence of anaemia** | 273 (54.4%) | 13 (50.0%) |  | 0.7 | 11 (55.0%) | 2 (33.3%) | 0.6 |
| **Viral load (log10 Copies/mL)** | 10.7 (7.3, 12.3) | 11.0 (10.7, 11.3) |  | 0.8 | 11.0 (10.7, 11.3) | NA (NA, NA) |  |
| **Total CD4 count** | 33.5 (15.0, 61.0) | 25.5 (13.3, 50.3) |  | 0.4 | 25.5 (13.8, 50.5) | 32.0 (9.8, 49.0) | >0.9 |
| **Sodium mmol/L** | 134.0 (130.0, 137.0) | 135.0 (133.0, 137.0) |  | 0.063 | 134.5 (131.8, 137.0) | 136.0 (135.3, 138.3) | 0.2 |
| **Potassium mmol/L** | 4.1 (3.7, 4.6) | 3.9 (3.3, 4.1) |  | 0.039 | 3.8 (3.3, 4.1) | 3.9 (3.4, 4.1) | 0.9 |
| **Haemoglobin g/dL** | 8.7 (7.4, 10.3) | 8.7 (7.6, 10.4) |  | 0.9 | 8.5 (7.7, 10.3) | 8.7 (6.7, 10.5) | >0.9 |
| **White cell count X109** | 5.4 (3.7, 8.1) | 4.7 (2.7, 9.8) |  | 0.5 | 4.5 (2.5, 7.6) | 5.2 (4.1, 11.2) | 0.3 |
| **Lymphocyte count X109** | 0.8 (0.4, 1.8) | 0.9 (0.5, 1.3) |  | 0.7 | 1.3 (1.0, 17.5) | 0.5 (0.4, 0.8) | 0.2 |
| **Neutrophils** | 3.7 (1.5, 8.9) | 1.0 (0.9, 1.5) |  | 0.012 | 0.7 (0.6, 0.8) | 1.5 (1.3, 1.6) | 0.2 |
| **3- month follow-up patient status** |  |  |  | 0.12 |  |  | 0.7 |
| Alive | 124 (24.8%) | 9 (34.6%) |  |  | 6 (30.0%) | 3 (50.0%) |  |
| Deceased –> EXIT form | 26 (5.2%) | 3 (11.5%) |  |  | 3 (15.0%) | 0 (0.0%) |  |
| Unknown | 351 (70.1%) | 14 (53.8%) |  |  | 11 (55.0%) | 3 (50.0%) |  |
| **6-month follow-up patient status** |  |  |  | 0.045 |  |  | >0.9 |
| Alive | 134 (26.7%) | 8 (30.8%) |  |  | 6 (30.0%) | 2 (33.3%) |  |
| Deceased –> EXIT form | 34 (6.8%) | 5 (19.2%) |  |  | 4 (20.0%) | 1 (16.7%) |  |
| Unknown | 333 (66.5%) | 13 (50.0%) |  |  | 10 (50.0%) | 3 (50.0%) |  |
| **12-month follow-up patient status** |  |  |  | 0.065 |  |  | 0.5 |
| Alive | 168 (33.5%) | 11 (42.3%) |  |  | 7 (35.0%) | 4 (66.7%) |  |
| Deceased –> EXIT form | 44 (8.8%) | 5 (19.2%) |  |  | 4 (20.0%) | 1 (16.7%) |  |
| Unknown | 289 (57.7%) | 10 (38.5%) |  |  | 9 (45.0%) | 1 (16.7%) |  |

Table 5

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variable | **Died without AI**, N = 58 | **Died with AI**, N = 6 | **p-value** | **Alive**, N = 20 | **Died**, N = 6 | **p-value** |
| **Age at enrolment median (IQR) (years)** | 39 (33, 45) | 41 (33, 46) | 0.7 | 36.0 (32.5, 44.0) | 40.5 (33.3, 46.3) | 0.7 |
| **Gender, n(%)** |  |  | >0.9 |  |  | >0.9 |
| Female | 32 (55.2%) | 3 (50.0%) |  | 11 (55.0%) | 3 (50.0%) |  |
| Male | 26 (44.8%) | 3 (50.0%) |  | 9 (45.0%) | 3 (50.0%) |  |
| Unknown | 0 (0.0%) | 0 (0.0%) |  | 0 (0.0%) | 0 (0.0%) |  |
| **Ethnicity, n(%)** |  |  | 0.2 |  |  | 0.12 |
| Black African | 50 (86.2%) | 4 (66.7%) |  | 19 (95.0%) | 4 (66.7%) |  |
| Other | 8 (13.8%) | 2 (33.3%) |  | 1 (5.0%) | 2 (33.3%) |  |
| **Duration of current illness, median (IQR) (days)** | NA (NA, NA) | NA (NA, NA) |  | NA (NA, NA) | NA (NA, NA) |  |
| **Random cortisol** | 481 (369, 616) | 307 (262, 336) | 0.003 | 316.0 (236.0, 381.5) | 306.5 (261.5, 335.8) | >0.9 |
| **Basal cortisol** | 500 (433, 636) | 308 (246, 365) | <0.001 | 292.0 (184.0, 354.5) | 308.0 (246.3, 364.5) | 0.6 |
| **Stimulated cortisol** | 795 (662, 890) | 375 (338, 424) | <0.001 | 398.5 (312.5, 465.3) | 375.0 (338.0, 424.0) | 0.7 |
| **ACTH** | 40 (25, 59) | 42 (26, 78) | 0.8 | 26.3 (20.2, 65.9) | 42.4 (25.7, 77.7) | 0.6 |
| **BP (systolic)** | 110 (102, 120) | 128 (122, 130) | 0.051 | 120.0 (103.3, 128.3) | 127.5 (121.8, 129.5) | 0.2 |
| **BP (diastolic)** | 70 (66, 80) | 74 (65, 78) | >0.9 | 72.0 (67.5, 81.3) | 73.5 (65.0, 78.3) | 0.7 |
| **Heart rate** | 93 (82, 109) | 87 (72, 98) | 0.2 | 86.5 (79.3, 114.0) | 87.0 (71.5, 98.0) | 0.4 |
| **Hypotension** | 7 (12.1%) | 0 (0.0%) | >0.9 | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Weakness** | 52 (89.7%) | 4 (66.7%) | 0.2 | 17 (85.0%) | 4 (66.7%) | 0.6 |
| **Tiredness** | 50 (86.2%) | 6 (100.0%) | >0.9 | 17 (85.0%) | 6 (100.0%) | >0.9 |
| **Poor appetite** | 49 (84.5%) | 6 (100.0%) | 0.6 | 16 (80.0%) | 6 (100.0%) | 0.5 |
| **Weight loss** | 50 (86.2%) | 4 (66.7%) | 0.2 | 17 (85.0%) | 4 (66.7%) | 0.6 |
| **Increased pigmentation of the skin** | 35 (60.3%) | 2 (33.3%) | 0.2 | 7 (35.0%) | 2 (33.3%) | >0.9 |
| **Nausea** | 36 (62.1%) | 5 (83.3%) | 0.4 | 11 (55.0%) | 5 (83.3%) | 0.4 |
| **Vomiting** | 15 (25.9%) | 2 (33.3%) | 0.7 | 6 (30.0%) | 2 (33.3%) | >0.9 |
| **Liking for salt** | 38 (65.5%) | 4 (66.7%) | >0.9 | 14 (70.0%) | 4 (66.7%) | >0.9 |
| **Hypoglycaemia** | 2 (3.4%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Loss of consciousness** | 2 (3.4%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Diarrhoea** | 32 (55.2%) | 1 (16.7%) | 0.10 | 7 (35.0%) | 1 (16.7%) | 0.6 |
| **Dizziness** | 33 (56.9%) | 3 (50.0%) | >0.9 | 10 (50.0%) | 3 (50.0%) | >0.9 |
| **Shock** | 2 (3.4%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **Anorexia** | 34 (58.6%) | 2 (33.3%) | 0.4 | 6 (30.0%) | 2 (33.3%) | >0.9 |
| **Loss of axillary and pubic hair, if female** |  |  | 0.8 |  |  | >0.9 |
| No | 16 (27.6%) | 2 (33.3%) |  | 9 (45.0%) | 2 (33.3%) |  |
| Not applicable | 23 (39.7%) | 3 (50.0%) |  | 9 (45.0%) | 3 (50.0%) |  |
| Yes | 19 (32.8%) | 1 (16.7%) |  | 2 (10.0%) | 1 (16.7%) |  |
| **Any postural drop in blood pressure** | 4 (6.9%) | 0 (0.0%) | >0.9 | 2 (10.0%) | 0 (0.0%) | >0.9 |
| **Presence of anaemia** | 36 (62.1%) | 3 (50.0%) | 0.7 | 10 (50.0%) | 3 (50.0%) | >0.9 |
| **Tuberculosis** | 47 (81.0%) | 5 (83.3%) | >0.9 | 15 (75.0%) | 5 (83.3%) | >0.9 |
| **Cryptococcus neoformans** | 3 (5.2%) | 3 (50.0%) | 0.009 | 7 (35.0%) | 3 (50.0%) | 0.6 |
| **Pneumonia** | 7 (12.1%) | 0 (0.0%) | >0.9 | 3 (15.0%) | 0 (0.0%) | >0.9 |
| **Staph aureus** | 0 (0.0%) | 0 (0.0%) |  | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Kaposis sarcoma** | 0 (0.0%) | 0 (0.0%) |  | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Cytomegalovirus** | 0 (0.0%) | 0 (0.0%) |  | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **HSV** | 1 (1.7%) | 0 (0.0%) | >0.9 | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **HepB** | 0 (0.0%) | 1 (16.7%) | 0.094 | 1 (5.0%) | 1 (16.7%) | 0.4 |
| **Candida** | 4 (6.9%) | 0 (0.0%) | >0.9 | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **GE/c diff** | 0 (0.0%) | 0 (0.0%) |  | 0 (0.0%) | 0 (0.0%) |  |
| **Parvo B19** | 0 (0.0%) | 0 (0.0%) |  | 1 (5.0%) | 0 (0.0%) | >0.9 |
| **Syphilis** | 2 (3.4%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **B menigitis** | 1 (1.7%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **UTI / Leptospirosis** | 1 (1.7%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **PCP** | 2 (3.4%) | 0 (0.0%) | >0.9 | 0 (0.0%) | 0 (0.0%) |  |
| **COVID-19** | 0 (0.0%) | 0 (0.0%) |  | 0 (0.0%) | 0 (0.0%) |  |
| **Neurocysticercosis** | 0 (0.0%) | 0 (0.0%) |  | 0 (0.0%) | 0 (0.0%) |  |
| **Viral load (log10 Copies/mL)** | 12.00 (10.29, 13.14) | NA (NA, NA) |  | 11.03 (10.74, 11.32)a | NA (NA, NA) | >0.9 |
| 10.4579184937828 |  |  |  | 1 (50.0%) | 0 (NA%) |  |
| 11.60516730587 |  |  |  | 1 (50.0%) | 0 (NA%) |  |
| **Total CD4 count** | 26 (13, 54) | 30 (16, 45) | 0.7 | 25.5 (10.0, 52.8) | 30.0 (15.5, 45.3) | 0.8 |
| **Sodium mmol/L** | 133.0 (127.5, 136.0) | 136.5 (133.3, 139.0) | 0.2 | 135.0 (132.8, 136.3) | 136.5 (133.3, 139.0) | 0.6 |
| **Potassium mmol/L** | 3.90 (3.60, 4.60) | 3.70 (3.37, 3.88) | 0.092 | 4.0 (3.3, 4.6) | 3.7 (3.4, 3.9) | 0.4 |
| **Haemoglobin g/dL** | 8.35 (7.05, 9.67) | 9.60 (8.25, 10.95) | 0.4 | 8.5 (7.6, 10.2) | 9.6 (8.3, 11.0) | 0.4 |
| **White cell count X109** | 5.0 (3.4, 7.4) | 8.3 (4.3, 27.5) | 0.2 | 4.1 (2.5, 6.3) | 8.3 (4.3, 27.5) | 0.2 |
| **Lymphocyte count X109** | 0.80 (0.40, 0.99) | NA (NA, NA) |  | 0.85 (0.52, 1.26) | NA (NA, NA) | >0.9 |

a Only two people had viral load results